PARP1 and central nervous system cancer: However, when the pharmacokinetic parameters of talazoparib were compared to another PARP in normal rodents, a low ratio of brain-plasma concentration of talazoparib (approximately 0.02) was observed, indicating that it lacks effectiveness in the orthotopic type of glioma models (Parrish et al., 2015; Kizilbash et al., 2017).